Director/PDMR Shareholding

RNS Number : 6340C

Mediclinic International plc

18 June 2019

 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

18 June 2019

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

On 14 June 2019, Mr Jurgens Myburgh, Chief Financial Officer of Mediclinic International plc, acquired 3,000 shares in the Company at ZAR 57.14 per share. Accordingly, Mr Myburgh now owns a total of 83,000 shares in Mediclinic International plc.

The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

1.	Details of PDMR / persons closely associated with them ("PCA")
a)	Name	Mr Petrus Jurgens Myburgh
2.	Reason for the notification
a)	Position / status	Chief Financial Officer of the Company
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	Price(s) Volume(s) ZAR 57.14 per share 3,000
d)	Aggregated information Aggregated volume Price	3,000 ZAR 57.14
e)	Date of the transaction	14 June 2019; 07:24 UTC
f)	Place of the transaction	Johannesburg Stock Exchange

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.

The Group's core purpose is to enhance the quality of life.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

Mediclinic comprises 77 hospitals, five sub-acute hospitals, 12 day case clinics and 21 outpatient clinics. Hirslanden operates 18 hospitals, two day case clinics and three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 52 hospitals, five sub-acute hospitals and 12 day case clinics with more than 8 500 inpatient beds; and Mediclinic Middle East operates seven hospitals, two day case clinics and 21 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

 

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

[phone]

Investor queries

James Arnold, Head of Investor Relations, Mediclinic International plc

[phone]

[e-mail] 

Media queries

FTI Consulting

Deborah Scott/Brett Pollard - United Kingdom

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

 

END

 

 

DSHBGGDLRDBBGCI